Prophylaxis

TB Chemoprophylaxis Underutilized in Elderly

Published in Medical Letter on the CDC and FDA, November 6th, 1995

Antituberculosis chemoprophylaxis is underutilized in older contacts of patients with active disease, according to a report from East Tennessee State University and the U.S. Centers for Disease Control and Prevention (CDC).

Isoniazid has been the main chemoprophylactic agent for the prevention of active tuberculosis since the early 1960s, when criteria were established for its use. Studies have shown, however, that isoniazid-induced hepatitis occurs in up to 3 percent of patients treated with the agent who are aged 50 or over. For this reason, many clinicians avoid preventive tuberculosis therapy in patients older than 35.

In this study researcher...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (1995-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry